| Revision as of 17:24, 14 January 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit |
Latest revision as of 14:12, 5 November 2022 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers170,014 edits +sd |
| (22 intermediate revisions by 16 users not shown) |
| Line 1: |
Line 1: |
|
|
{{short description|Chemical compound}} |
|
{{drugbox |
|
|
|
{{Drugbox |
| ⚫ |
| verifiedrevid = 407755991 |
|
|
|
| Verifiedfields = changed |
| ⚫ |
| IUPAC_name = (-)-ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropachromene-1a-carboxylate |
|
|
|
| Watchedfields = changed |
| ⚫ |
| image = CPCCOEt.svg |
|
|
⚫ |
| verifiedrevid = 407868970 |
| ⚫ |
| width = 200 |
|
|
⚫ |
| IUPAC_name = (−)-ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropachromene-1a-carboxylate |
| ⚫ |
| CAS_number = 179067-99-3 |
|
|
⚫ |
| image = CPCCOEt.svg |
|
| ATC_prefix = |
|
|
⚫ |
| width = 200 |
|
| ATC_suffix = |
|
|
|
|
| ⚫ |
| PubChem = 6278000 |
|
|
|
<!--Clinical data--> |
|
|
| tradename = |
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
|
|
|
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
⚫ |
| CAS_number = 179067-99-3 |
|
⚫ |
| PubChem = 6278000 |
|
| IUPHAR_ligand = 1382 |
|
| IUPHAR_ligand = 1382 |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
| C=13|H=13|N=1|O=4 |
|
|
|
| ChEMBL = 337583 |
|
| molecular_weight = 247.246 g/mol |
|
|
|
|
| ⚫ |
| smiles = CCOC(=O)C23Oc1ccccc1\C(=N\O)\C2C3 |
|
|
|
<!--Chemical data--> |
|
| bioavailability = |
|
|
| protein_bound = |
|
| C=13 | H=13 | N=1 | O=4 |
|
⚫ |
| smiles = CCOC(=O)C23Oc1ccccc1\C(=N\O)\C2C3 |
|
| metabolism = |
|
|
| elimination_half-life = |
|
|
| excretion = |
|
| ⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
|
| pregnancy_category= |
|
| ⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| ⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| ⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| ⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
|
| legal_status = |
|
|
| routes_of_administration = |
|
|
}} |
|
}} |
|
|
|
|
|
'''CPCCOEt''' is a drug used in scientific research, which acts as a non-competitive ] at the ] subtype ], with high selectivity although only moderate ].<ref name="pmid10051528">{{cite journal |author=Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R |title=CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding |journal=Molecular Pharmacology |volume=55 |issue=3 |pages=453–61 |year=1999 |month=March |pmid=10051528 |doi= |url=}}</ref><ref name="pmid11087567">{{cite journal |author=Ott D, Floersheim P, Inderbitzin W, Stoehr N, Francotte E, Lecis G, Richert P, Rihs G, Flor PJ, Kuhn R, Gasparini F |title=Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropanaphthalene-7a-carboxylic acid ethyl ester |journal=Journal of Medicinal Chemistry |volume=43 |issue=23 |pages=4428–36 |year=2000 |month=November |pmid=11087567 |doi= 10.1021/jm0009944|url=}}</ref> It is used mainly in basic research into the function of the mGluR<sub>1</sub> receptor,<ref name="pmid17045308">{{cite journal |author=Fukunaga I, Yeo CH, Batchelor AM |title=The mGlu1 antagonist CPCCOEt enhances the climbing fibre response in Purkinje neurones independently of glutamate receptors |journal=Neuropharmacology |volume=52 |issue=2 |pages=450–8 |year=2007 |month=February |pmid=17045308 |doi=10.1016/j.neuropharm.2006.08.014 |url=}}</ref><ref name="pmid18279362">{{cite journal |author=Sugiyama Y, Kawaguchi SY, Hirano T |title=mGluR1-mediated facilitation of long-term potentiation at inhibitory synapses on a cerebellar Purkinje neuron |journal=The European Journal of Neuroscience |volume=27 |issue=4 |pages=884–96 |year=2008 |month=February |pmid=18279362 |doi=10.1111/j.1460-9568.2008.06063.x |url=}}</ref> including the study of behavioural effects in animals including effects on memory and addiction.<ref name="pmid16697125">{{cite journal |author=Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK |title=Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties |journal=Drug and Alcohol Dependence |volume=85 |issue=2 |pages=142–56 |year=2006 |month=November |pmid=16697125 |doi=10.1016/j.drugalcdep.2006.04.003 |url=}}</ref><ref name="pmid17292864">{{cite journal |author=Kim J, Lee S, Park H, Song B, Hong I, Geum D, Shin K, Choi S |title=Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction |journal=Biochemical and Biophysical Research Communications |volume=355 |issue=1 |pages=188–93 |year=2007 |month=March |pmid=17292864 |doi=10.1016/j.bbrc.2007.01.125 |url=}}</ref> |
|
'''CPCCOEt''' is a drug used in scientific research, which acts as a non-competitive ] at the ] subtype ], with high selectivity although only moderate ].<ref name="pmid10051528">{{cite journal |vauthors=Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R |title=CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding |journal=Molecular Pharmacology |volume=55 |issue=3 |pages=453–61 |date=March 1999 |pmid=10051528 }}</ref><ref name="pmid11087567">{{cite journal |vauthors=Ott D, Floersheim P, Inderbitzin W, Stoehr N, Francotte E, Lecis G, Richert P, Rihs G, Flor PJ, Kuhn R, Gasparini F |title=Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropanaphthalene-7a-carboxylic acid ethyl ester |journal=Journal of Medicinal Chemistry |volume=43 |issue=23 |pages=4428–36 |date=November 2000 |pmid=11087567 |doi= 10.1021/jm0009944}}</ref> It is used mainly in basic research into the function of the mGluR<sub>1</sub> receptor,<ref name="pmid17045308">{{cite journal |vauthors=Fukunaga I, Yeo CH, Batchelor AM |title=The mGlu1 antagonist CPCCOEt enhances the climbing fibre response in Purkinje neurones independently of glutamate receptors |journal=Neuropharmacology |volume=52 |issue=2 |pages=450–8 |date=February 2007 |pmid=17045308 |doi=10.1016/j.neuropharm.2006.08.014 |s2cid=40361285 }}</ref><ref name="pmid18279362">{{cite journal |vauthors=Sugiyama Y, Kawaguchi SY, Hirano T |title=mGluR1-mediated facilitation of long-term potentiation at inhibitory synapses on a cerebellar Purkinje neuron |journal=The European Journal of Neuroscience |volume=27 |issue=4 |pages=884–96 |date=February 2008 |pmid=18279362 |doi=10.1111/j.1460-9568.2008.06063.x |s2cid=25581416 }}</ref> including the study of behavioural effects in animals including effects on memory and addiction.<ref name="pmid16697125">{{cite journal |vauthors=Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK |title=Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties |journal=Drug and Alcohol Dependence |volume=85 |issue=2 |pages=142–56 |date=November 2006 |pmid=16697125 |doi=10.1016/j.drugalcdep.2006.04.003 }}</ref><ref name="pmid17292864">{{cite journal |vauthors=Kim J, Lee S, Park H, Song B, Hong I, Geum D, Shin K, Choi S |title=Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction |journal=Biochemical and Biophysical Research Communications |volume=355 |issue=1 |pages=188–93 |date=March 2007 |pmid=17292864 |doi=10.1016/j.bbrc.2007.01.125 }}</ref> |
|
|
|
|
|
==See also== |
|
==See also== |
|
* ] |
|
* ] |
|
|
|
|
|
== References == |
|
==References== |
|
{{Reflist}} |
|
{{Reflist|2}} |
|
|
|
|
|
|
{{Metabotropic glutamate receptor modulators}} |
|
{{Glutamate_receptor_ligands}} |
|
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
|
{{pharm-stub}} |
|
{{nervous-system-drug-stub}} |